Lantheus Holdings, Inc. (LNTH) stock
LNTHNasdaqIn Vitro & In Vivo Diagnostic SubstancesFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3010% above fair value
$101.25−0.35 (-0.34%)
Close on Nov 12, 2026Market cap $6.61BP/E 25.0Yield –
Lantheus enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Lantheus's enterprise value was $6.61B on Nov 11, 2026, against $4.41B a year earlier. Over the last 5 years it ranged from $1.80B to $7.58B, with a median of $5.23B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $6.61B | +33.2% |
| 2025 | Dec 31, 2025 | $4.96B | -17.8% |
| 2024 | Dec 31, 2024 | $6.04B | +41.2% |
| 2023 | Dec 29, 2023 | $4.28B | +25.1% |
| 2022 | Dec 30, 2022 | $3.42B | +67.5% |
| 2021 | Dec 31, 2021 | $2.04B | +96.8% |
| 2020 | Dec 31, 2020 | $1.04B | +12.3% |
| 2019 | Dec 31, 2019 | $923.06M | +20.8% |
| 2018 | Dec 31, 2018 | $764.24M | -21.0% |
| 2017 | Dec 29, 2017 | $967.03M | +75.1% |
| 2016 | Dec 30, 2016 | $552.18M | +27.0% |
| 2015 | Dec 31, 2015 | $434.73M | – |
See a number that looks wrong?